The blood-brain barrier (BBB) is the central nervous system’s (CNS) most formidable defense, a highly selective semipermeable border that prevents 98% of small-molecule drugs and nearly all large-molecule therapeutics from reaching the brain. To treat neurodegenerative diseases, strokes, and brain tumors, researchers are developing strategies to circumvent this barrier entirely or hijack its internal transport mechanisms.
The Olfactory Shortcut
The most direct non-invasive route to the brain is the "nose-to-brain" pathway. Unlike the rest of the body, where the nervous system is shielded by bone and blood vessels, the olfactory mucosa in the upper nasal cavity provides a direct interface between the external environment and neural tissue.
As Meinhardt et al. (Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19) demonstrate, pathogens can exploit this pathway by migrating through sensory nerve endings. Therapeutic research aims to mirror this mechanism. Ma et al. (The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review) and Zhou et al. (A novel neuroprotective derived peptide of erythropoietin improved cognitive function in vascular dementia mice) explain that intranasal administration allows molecules to travel along the olfactory and trigeminal nerve pathways. This bypasses the BBB and avoids "first-pass" metabolism in the liver, achieving higher local concentrations in the brain with lower systemic exposure.
This route is particularly effective for delicate or large therapeutic agents. Zhao et al. (Mitochondrion-based organellar therapies for central nervous system diseases) suggest that even whole organelles, like mitochondria, can be delivered via the nasal pathway to restore energy production in damaged neurons without being sequestered by the lungs or liver.
Direct Fluid Administration
When non-invasive routes are insufficient, clinicians use the cerebrospinal fluid (CSF) as a delivery vehicle. By injecting therapeutics directly into the spinal canal (intrathecal) or the brain's ventricles (intracerebroventricular), the BBB is physically bypassed.
Kishima et al. (Neurosurgical Approach for Spasticity) highlight that intrathecal delivery allows for high therapeutic concentrations at the spinal cord level using only a fraction of the oral dose, which significantly reduces systemic side effects. Similarly, Cook et al. (Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans) show that intrathecal administration is the clinical standard for antisense oligonucleotides (ASOs), ensuring these large molecules reach the deep tissues of the brain and spinal cord.
For aggressive conditions like brain tumors, Majzner et al. (GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas) found that delivering CAR T cells directly into the ventricles (ICV) resulted in higher pro-inflammatory cytokine levels within the CSF and less systemic toxicity compared to traditional intravenous delivery.
Hijacking Barrier Transporters
A third strategy involves engineering "Trojan Horse" nanocarriers that the BBB actively pulls into the brain. Instead of breaking through the barrier, these carriers exploit natural gatekeeper mechanisms.
Gajbhiye et al. (Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study) demonstrated this by tethering Vitamin C (ascorbic acid) to nanoparticles. Because the brain has a high demand for Vitamin C, it uses SVCT2 transporters to pull these particles across the barrier. Similarly, Formicola et al. (The synergistic effect of chlorotoxin-mApoE in boosting drug-loaded liposomes across the BBB) showed that liposomes functionalized with specific peptides can trigger transcytosis—a process where the endothelial cells of the BBB engulf the carrier on one side and release it on the other—without disrupting the barrier's protective tight junctions.
Cell-Free Delivery via Exosomes
Recent work has pivoted toward exosomes—tiny, naturally occurring vesicles—as a "cell-free" alternative to stem cell therapy. Exosomes are small enough to cross the BBB and can be loaded with specific therapeutic cargo.
Gu et al. (Safety and biodistribution of exosomes derived from human induced pluripotent stem cells) found that exosomes derived from induced pluripotent stem cells can target diseased brain tissue in Parkinson’s models without the tumorigenic risks of whole-cell transplants. When combined with intranasal delivery, as noted by Ting Zhang et al. (Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives), these vesicles provide a targeted, low-toxicity method for delivering anti-inflammatory agents directly to the site of neurodegeneration.
Key Foundational Work
Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006 (2006) — contributed 1 concept elements to this direction.
The impact of environmental metals in young urbanites’ brains (2012) — contributed 1 concept elements to this direction.